Morgan Stanley Maintains Equal-Weight on Lakefront Biotherapeutics, Raises Price Target to $27

Benzinga · 4d ago
Morgan Stanley analyst Judah Frommer maintains Lakefront Biotherapeutics (NASDAQ:LKFT) with a Equal-Weight and raises the price target from $26 to $27.